These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21902681)

  • 1. KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.
    Miki H; Ozaki S; Nakamura S; Oda A; Amou H; Ikegame A; Watanabe K; Hiasa M; Cui Q; Harada T; Fujii S; Nakano A; Kagawa K; Takeuchi K; Yata K; Sakai A; Abe M; Matsumoto T
    Br J Haematol; 2011 Nov; 155(3):328-39. PubMed ID: 21902681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500.
    Kamishohara M; Kenney S; Domergue R; Vistica DT; Sausville EA
    Exp Cell Res; 2000 May; 256(2):468-79. PubMed ID: 10772819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.
    Kamishohara M; Kawai H; Sakai T; Isoe T; Hasegawa K; Mochizuki J; Uchida T; Kataoka S; Yamaki H; Tsuruo T
    Oncol Res; 1994; 6(8):383-90. PubMed ID: 7894087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
    Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
    Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
    Yata K; Yaccoby S
    Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.
    Sekimoto E; Ozaki S; Ohshima T; Shibata H; Hashimoto T; Abe M; Kimura N; Hattori K; Kawai S; Kinoshita Y; Yamada-Okabe H; Tsuchiya M; Matsumoto T
    Cancer Res; 2007 Feb; 67(3):1184-92. PubMed ID: 17283154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells.
    Nakamura S; Kobayashi M; Shibata K; Sahara N; Shigeno K; Shinjo K; Naito K; Hayashi H; Ohnishi K
    Leuk Res; 2006 Feb; 30(2):123-35. PubMed ID: 16046235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo.
    Wu KD; Cho YS; Katz J; Ponomarev V; Chen-Kiang S; Danishefsky SJ; Moore MA
    Proc Natl Acad Sci U S A; 2005 Jul; 102(30):10640-5. PubMed ID: 16030145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
    Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
    Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen.
    Kamishohara M; Kawai H; Sakai T; Uchida T; Tsuruo T; Otake N
    Cancer Chemother Pharmacol; 1996; 38(6):495-8. PubMed ID: 8823489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcuma wenyujin extract induces apoptosis and inhibits proliferation of human cervical cancer cells in vitro and in vivo.
    Lim CB; Ky N; Ng HM; Hamza MS; Zhao Y
    Integr Cancer Ther; 2010 Mar; 9(1):36-49. PubMed ID: 20150221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein.
    Zhang WJ; Ohnishi K; Yoshida H; Pan L; Maksumova L; Muratkhodjaev F; Luo JM; Shigeno K; Fujisawa S; Naito K; Nakamura S; Shinjo K; Takeshita A; Ohno R
    Jpn J Cancer Res; 2000 Jun; 91(6):604-11. PubMed ID: 10874212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.